These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29534302)

  • 21. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
    Fierbinteanu-Braticevici C; Sinescu C; Moldoveanu A; Petrisor A; Diaconu S; Cretoiu D; Braticevici B
    Cell Biol Toxicol; 2017 Feb; 33(1):5-14. PubMed ID: 27680752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rediscussion on linearity between fibrosis stages and mortality risk in nonalcoholic fatty liver disease patients.
    Liu Z; Que S; Mardinoglu A
    Hepatology; 2017 Oct; 66(4):1357-1358. PubMed ID: 28727167
    [No Abstract]   [Full Text] [Related]  

  • 25. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to letter to the editor by Kawada on "Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke".
    Parikh NS; Gutierrez J
    J Neurol Sci; 2020 Jan; 408():116574. PubMed ID: 31732172
    [No Abstract]   [Full Text] [Related]  

  • 28. Comments on "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis".
    Safiri S; Khazaei S; Mansori K; Ayubi E
    Hepatology; 2017 Oct; 66(4):1358-1359. PubMed ID: 28727154
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Pandey S
    Hepatology; 2020 Feb; 71(2):763-764. PubMed ID: 31393627
    [No Abstract]   [Full Text] [Related]  

  • 30. The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease.
    Nostedt JJ; Switzer NJ; Gill RS; Dang J; Birch DW; de Gara C; Bailey RJ; Karmali S
    Can J Gastroenterol Hepatol; 2016; 2016():2059245. PubMed ID: 27777925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daily Aspirin Use Associated With Reduced Risk for Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease.
    Severo MD
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):523. PubMed ID: 31937400
    [No Abstract]   [Full Text] [Related]  

  • 33. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
    Angulo P; Machado MV; Diehl AM
    Semin Liver Dis; 2015 May; 35(2):132-45. PubMed ID: 25974899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease and fibrosis progression: the good, the bad, and the unknown.
    Harrison SA
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):655-7. PubMed ID: 25478921
    [No Abstract]   [Full Text] [Related]  

  • 35. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of non-invasive fibrosis tests: a solution for the prediction of advanced fibrosis in non-alcoholic fatty liver disease?
    Lupşor-Platon M
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):257-259. PubMed ID: 31517316
    [No Abstract]   [Full Text] [Related]  

  • 37. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease.
    Mandelia C; Kabbany MN; Conjeevaram Selvakumar PK; Alkhouri N
    Biomark Med; 2018 Mar; 12(3):265-273. PubMed ID: 29517271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis.
    Osayande AS; Kale N
    Am Fam Physician; 2017 Jun; 95(12):796-797. PubMed ID: 28671424
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.